Moleculin Biotech, Inc

(NASDAQ:MBRX)

Latest On Moleculin Biotech, Inc (MBRX):

Date/Time Type Description Signal Details
2023-05-11 21:54 ESTNewsMoleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call TranscriptN/A
2023-05-11 07:42 ESTNewsMoleculin Biotech GAAP EPS of -$0.28 in-lineN/A
2023-03-23 21:24 ESTNewsMoleculin Biotech reports FY resultsN/A
2023-03-23 21:24 ESTNewsMoleculin drops as 2022 net loss widensN/A
2023-03-23 21:24 ESTNewsMoleculin Biotech, Inc. (MBRX) Q4 2022 Earnings Call TranscriptN/A
2022-12-15 12:07 ESTNewsMoleculin drug shows promise in interim data from phase 1 trial in blood cancerN/A
2022-12-07 16:09 ESTNewsFDA grants fast track designation to Moleculin Biotech's treatment for brain cancerN/A
2022-11-13 01:13 ESTNewsMoleculin Biotech, Inc. (MBRX) Q3 2022 Earnings Call TranscriptN/A
2022-11-10 19:35 ESTNewsMoleculin Biotech GAAP EPS of -$0.30N/A
2022-09-27 13:36 ESTNewsMoleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studiesN/A
2022-09-06 11:13 ESTNewsMoleculin brain cancer therapy WP1122 gets FDA orphan drug statusN/A
2022-08-15 18:03 ESTNewsMoleculin Biotech GAAP EPS of -$0.24N/A
2022-07-08 22:27 ESTNewsMoleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trialN/A
2022-05-26 14:21 ESTNewsMoleculin begins human trial of WP1122 to treat COVID-19N/A
2022-05-12 19:50 ESTNewsMoleculin Biotech GAAP EPS of -$0.24 misses by $0.01N/A
2022-04-21 21:08 ESTNewsMoleculin cleared to conduct phase 1 study of WP1066 for treatment of recurrent brain tumorN/A
2022-03-26 04:15 ESTNewsMoleculin Biotech GAAP EPS of -$0.59 beats by $0.12N/A
2021-12-02 01:02 ESTNewsMoleculin gains 5% on FDA green light for Phase 1 study of WP1122 in glioblastoma multiformeN/A
2021-10-19 14:15 ESTNewsMHRA OKs phase 1 trial of Moleculin Biotech's COVID-19 treatmentN/A
2021-10-18 17:19 ESTNewsMoleculin says no dose-limiting toxicity in early-stage study for lung cancer therapyN/A
2021-08-12 20:13 ESTNewsMoleculin Biotech EPS beats by $0.05N/A
2021-07-21 15:06 ESTNewsMoleculin kicks off phase 1b/2 annamycin cancer trialN/A
2021-07-21 14:53 ESTNewsMoleculin Biotech to join Russell 2000 IndexN/A
2021-07-21 14:50 ESTNewsMoleculin starts enrollment in phase 1b/2 annamycin sarcoma lung metastases studyN/A
2021-07-21 14:31 ESTNewsMoleculin gets approval to amend protocol in early-stage annamycin leukemia studyN/A
2021-04-14 10:18 ESTNewsMoleculin (MBRX) shares surge 9% on Rare Pediatric status for WP1066 in ependymomaN/A
2021-03-30 09:09 ESTNewsMoleculin Biotech wins second FDA Fast Track Designation for AnnamycinN/A
2021-03-24 21:15 ESTNewsMoleculin Biotech EPS beats by $0.37N/A
2021-02-11 09:18 ESTNewsUnderwriters exercise over-allotment option in Moleculin offeringN/A
2021-02-10 14:30 ESTNewsMoleculin Biotech: Some Recent Momentum On A Beaten-Down NameN/A
2021-02-05 11:00 ESTNewsMoleculin Biotech's annamycin brings 100% survival rate in osteosarcoma lung metastases in animalsN/A
2021-02-02 12:14 ESTAnalyst RatingThe Analyst Target Price has increased from $3.33 to $19.67.Buy
2021-02-02 10:11 ESTNewsMoleculin shares soar after promising Annamycin pre-clinical readoutN/A
2021-02-02 00:11 ESTStock SplitA stock split has occured on Feb 1, 2021 with a split factor of 1:6.Neutral
2021-01-29 20:19 ESTNewsMoleculin Biotech under pressure on reverse stock splitN/A
2021-01-06 16:07 ESTFinancialsCompany financials have been released.Neutral
2020-12-29 18:49 ESTNewsMoleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomasN/A
2020-12-17 20:13 ESTNewsMoleculin Bio on go with mid-stage study of Annamycin for lung metastasesN/A
2020-12-01 22:07 ESTNewsFDA Rare Pediatric tags for WP1066 lifts Moleculin BiotechN/A
2020-11-26 20:46 ESTFinancialsCompany financials have been released.Neutral
2020-11-19 21:54 ESTNewsMoleculin Biotech's annamycin shows encouraging action in animal studyN/A
2020-11-17 04:39 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 06:35 ESTNewsMoleculin Biotech EPS beats by $0.04N/A
2020-11-07 16:25 ESTFinancialsCompany financials have been released.Neutral
2020-10-31 20:27 ESTNewsMoleculin further collaborates to advance WP1122 in COVID-19N/A
2020-10-13 13:08 ESTNewsMoleculin reports additional positive interim results in adult glioblastoma trialN/A
2020-10-06 16:20 ESTNewsMoleculin pipeline candidates show potential activity against HIVN/A
2020-10-01 17:09 ESTNewsMoleculin's WP1066 shows encouraging action in early-stage pediatric brain tumor studyN/A
2020-09-30 09:49 ESTNewsMoleculin Biotech discovers additional anti-SARS-CoV-2 moleculeN/A
2020-09-26 13:20 ESTFinancialsCompany financials have been released.Neutral

About Moleculin Biotech, Inc (MBRX):

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. The company has partnerships and collaboration agreement with The University of Texas MD Anderson Cancer Center, Emory University, Mayo Clinic Research Endeavor, The University of Iowa, Medical University of Gdansk, University of Bergen, DERMIN Sp. z o. o., and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

MBRX Quotes by TradingView

See Advanced Chart

General

  • Name Moleculin Biotech, Inc
  • Symbol MBRX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 11
  • Last Split Factor1:6
  • Last Split Date2021-02-01
  • Fiscal Year EndDecember
  • IPO Date2016-06-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.moleculin.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 8.31
View More

Financials

  • Most Recent Quarter 2020-09-30
  • Next Quarter EPS Estimate -$0.10
  • Return on Assets -46%
  • Return on Equity -111%
  • Earnings Per Share -$0.32
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 122.21 million
  • EBITDA -14983000
  • Analyst Target Price $19.67
  • Book Value Per Share $1.41
View More

Share Statistics

  • Shares Outstanding 28.42 million
  • Shares Float 9.99 million
  • % Held by Insiders 1116%
  • % Held by Institutions 22.85%
  • Shares Short 602462
  • Shares Short Prior Month 416454
  • Short Ratio 0.11
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 2.08
  • 52 Week High $9.3
  • 52 Week Low $3.16
  • 50 Day Moving Average 4.7
  • 200 Day Moving Average 4.87
View More

Dividends

  • Dividend Date 2021-02-01
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Moleculin Biotech, Inc (MBRX) Dividend Calendar:

MBRX's last dividend payment was made to shareholders on February 1, 2021.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Moleculin Biotech, Inc (MBRX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-09-302020-11-12$N/A-$0.60-$0.56-6.98%
2020-06-302020-08-12$N/A-$0.51-$0.546.35%
2020-03-312020-05-11$N/A-$0.61-$0.60-1.2%
2019-12-312020-03-19$N/A-$0.67-$0.60-10.9%
2019-09-302019-11-12$N/A-$0.56-$0.52-8.23%
2019-06-302019-08-16$N/A-$0.51-$0.7228.67%
2019-03-312019-05-13$N/A-$0.84-$0.54-55.56%
2018-12-312019-02-21$N/A-$0.60-$0.600%
2018-09-302018-11-13$N/A-$0.48-$0.7838.46%
2018-06-302018-08-10$N/A-$1.20-$0.84-42.86%
2018-03-312018-05-14$N/A-$0.68-$0.8419.29%
2017-12-312018-03-28$N/A-$1.01-$0.72-40.32%
2017-09-302017-11-13$N/A-$0.84
2017-06-302017-08-14$N/A-$0.19
2017-03-312017-04-03$N/A-$0.12-$0.11-9.09%
2016-09-302016-11-21$N/A-$0.12-$0.11-12.45%
2016-06-302016-08-15$N/A-$0.08

Moleculin Biotech, Inc (MBRX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Research Development 4.44 million N/A 3.21 million 3.2 million 2.79 million
Income Before Tax -3.4 million N/A -1.21 million -3.8 million -4.37 million
Selling General Administrative 1.66 million N/A 1.81 million 1.56 million 1.67 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -6.09 million N/A -5.02 million -4.81 million -4.51 million
Operating Income -6.15 million N/A -5.06 million -4.81 million -4.51 million
Income Tax Expense N/A N/A N/A N/A -229000
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net 2.75 million N/A 3.85 million 1.02 million 134000
Net Income From Continuing Operations -3.4 million N/A -1.21 million -3.8 million -4.15 million
Net Income Applicable to Common Shares -3.4 million -10.11 million N/A -3.8 million -4.15 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments -340000 -18000 -2000 N/A N/A
Change to Liabilities -575000 712000 N/A -1.04 million 1.93 million
Total Cash Flow from Investing Activities -340000 -18000 N/A -9000 -8000
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities 1.76 million 10.01 million 5.29 million N/A 52000
Change to Operating Activities 830000 -1.09 million N/A 729000 -2.01 million
Change in Cash -3.94 million 5.09 million 914000 -4.67 million -3.29 million
Total Cash from Operating Activities -5.37 million -4.93 million -4.34 million -4.68 million -3.33 million
Depreciation 56000 52000 46000 52000 50000
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income -2.29 million 5.5 million N/A -626000 852000
Capital Expenditures 340000 18000 2000 10000 8000
Balance Sheet:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Total Liabailities 12.68 million 15.75 million 10.18 million 9.66 million 11.42 million
Total Stockholder Equity 14.47 million 15.63 million 15.29 million 15.57 million 18.98 million
Other Current Liabilities N/A 75000 N/A 99000 6.82 million
Total Assets 27.14 million 31.38 million 25.47 million 25.24 million 30.4 million
Common Stock 62000 60000 N/A 46000 46000
Other Current Assets 257000 436000 615000 2.39 million N/A
Retained Earnings -54.28 million -50.88 million -40.77 million -39.56 million -35.76 million
Other Liabilities 9.05 million 11.79 million N/A 5.82 million N/A
Other Assets N/A N/A N/A N/A N/A
Cash 12.8 million 16.73 million 11.65 million 10.74 million 15.41 million
Total Current Liabilities 3.44 million 3.74 million 3.24 million 3.57 million 11.12 million
Other Stockholder Equity 33000 23000 N/A 31000 19000
Property, Plant & Equipment 746000 483000 N/A 603000 664000
Total Current Assets 15.25 million 19.75 million 13.79 million 13.48 million 18.59 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 3.32 million 4.48 million N/A 4.42 million 7.83 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 1.34 million 1.92 million 1.21 million 2.15 million 3.19 million

Moleculin Biotech, Inc (MBRX) Chart:

Moleculin Biotech, Inc (MBRX) News:

Below you will find a list of latest news for Moleculin Biotech, Inc (MBRX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Moleculin Biotech, Inc (MBRX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest MBRX Trades:

Date Shares Price
Jun 13, 2022 2:42 PM EST300$1.39

Moleculin Biotech, Inc (MBRX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000165/0001659617-20-000165-index.htm
2018-07-19UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1659617/000000000018022235/0000000000-18-022235-index.htm
2018-10-23UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1659617/000000000018033221/0000000000-18-033221-index.htm
2020-01-06UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1659617/000000000020000106/0000000000-20-000106-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000090266420000870/0000902664-20-000870-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000091957419002792/0000919574-19-002792-index.htm
2019-05-02SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000110465919026299/0001104659-19-026299-index.htm
2020-02-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000110465920011647/0001104659-20-011647-index.htm
2020-02-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000110465920011650/0001104659-20-011650-index.htm
2020-02-06424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000110465920012016/0001104659-20-012016-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000110465920013411/0001104659-20-013411-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000110465920016402/0001104659-20-016402-index.htm
2020-07-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000110465920084557/0001104659-20-084557-index.htm
2020-07-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000110465920084563/0001104659-20-084563-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000114420418033608/0001144204-18-033608-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000114420418033609/0001144204-18-033609-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000114420418033610/0001144204-18-033610-index.htm
2018-06-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000114420418035170/0001144204-18-035170-index.htm
2018-06-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420418035173/0001144204-18-035173-index.htm
2018-10-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420418052779/0001144204-18-052779-index.htm
2018-10-15S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000114420418053847/0001144204-18-053847-index.htm
2018-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420418053855/0001144204-18-053855-index.htm
2018-10-25S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000114420418055201/0001144204-18-055201-index.htm
2018-10-24CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1659617/000114420418055202/0001144204-18-055202-index.htm
2018-10-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1659617/000114420418055246/0001144204-18-055246-index.htm
2018-10-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1659617/000114420418055247/0001144204-18-055247-index.htm
2018-10-29424B3Prospectus [Rule 424(b)(3)]https://www.sec.gov/Archives/edgar/data/1659617/000114420418055878/0001144204-18-055878-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420419000916/0001144204-19-000916-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420419001760/0001144204-19-001760-index.htm
2019-03-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000114420419016030/0001144204-19-016030-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420419016392/0001144204-19-016392-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000114420419016728/0001144204-19-016728-index.htm
2019-04-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420419020801/0001144204-19-020801-index.htm
2019-04-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000114420419020802/0001144204-19-020802-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000114420419028195/0001144204-19-028195-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000114420419028196/0001144204-19-028196-index.htm
2019-05-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000114420419028197/0001144204-19-028197-index.htm
2019-07-24424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1659617/000114420419035669/0001144204-19-035669-index.htm
2019-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000114420419035673/0001144204-19-035673-index.htm
2020-09-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920019124/0001437749-20-019124-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920019447/0001437749-20-019447-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920019673/0001437749-20-019673-index.htm
2020-09-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920019676/0001437749-20-019676-index.htm
2020-09-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020383/0001437749-20-020383-index.htm
2020-10-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020551/0001437749-20-020551-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020687/0001437749-20-020687-index.htm
2020-10-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020741/0001437749-20-020741-index.htm
2020-10-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020742/0001437749-20-020742-index.htm
2020-10-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020761/0001437749-20-020761-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920020853/0001437749-20-020853-index.htm
2020-10-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920021042/0001437749-20-021042-index.htm
2020-10-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920021357/0001437749-20-021357-index.htm
2020-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000143774920021911/0001437749-20-021911-index.htm
2019-01-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000153561019000016/0001535610-19-000016-index.htm
2019-04-23SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000153561019000082/0001535610-19-000082-index.htm
2020-01-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000153561020000019/0001535610-20-000019-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1659617/000153561020000066/0001535610-20-000066-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000071/0001659617-18-000071-index.htm
2018-06-25S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000074/0001659617-18-000074-index.htm
2018-06-27S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendmentshttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000077/0001659617-18-000077-index.htm
2018-07-12S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000165961718000084/0001659617-18-000084-index.htm
2018-07-19CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000086/0001659617-18-000086-index.htm
2018-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961718000093/0001659617-18-000093-index.htm
2018-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000096/0001659617-18-000096-index.htm
2018-09-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000103/0001659617-18-000103-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961718000109/0001659617-18-000109-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000110/0001659617-18-000110-index.htm
2018-12-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961718000112/0001659617-18-000112-index.htm
2019-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000003/0001659617-19-000003-index.htm
2019-02-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000005/0001659617-19-000005-index.htm
2019-02-2110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1659617/000165961719000018/0001659617-19-000018-index.htm
2019-02-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000019/0001659617-19-000019-index.htm
2019-03-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000022/0001659617-19-000022-index.htm
2019-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000025/0001659617-19-000025-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000030/0001659617-19-000030-index.htm
2019-04-05PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000033/0001659617-19-000033-index.htm
2019-04-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000037/0001659617-19-000037-index.htm
2019-04-12PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000042/0001659617-19-000042-index.htm
2019-04-16DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000047/0001659617-19-000047-index.htm
2019-04-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000057/0001659617-19-000057-index.htm
2019-05-03DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000059/0001659617-19-000059-index.htm
2019-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000062/0001659617-19-000062-index.htm
2019-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961719000069/0001659617-19-000069-index.htm
2019-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000072/0001659617-19-000072-index.htm
2019-05-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000077/0001659617-19-000077-index.htm
2019-05-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000080/0001659617-19-000080-index.htm
2019-07-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000084/0001659617-19-000084-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000101/0001659617-19-000101-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000102/0001659617-19-000102-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000103/0001659617-19-000103-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000104/0001659617-19-000104-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000105/0001659617-19-000105-index.htm
2019-07-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000106/0001659617-19-000106-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000107/0001659617-19-000107-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000114/0001659617-19-000114-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000118/0001659617-19-000118-index.htm
2019-08-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000125/0001659617-19-000125-index.htm
2019-08-14NT 10-QNotification of inability to timely file Form 10-Q or 10-QSBhttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000137/0001659617-19-000137-index.htm
2019-08-1610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961719000144/0001659617-19-000144-index.htm
2019-08-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000145/0001659617-19-000145-index.htm
2019-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000152/0001659617-19-000152-index.htm
2019-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000159/0001659617-19-000159-index.htm
2019-10-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000161/0001659617-19-000161-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961719000169/0001659617-19-000169-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000170/0001659617-19-000170-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000173/0001659617-19-000173-index.htm
2019-11-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000177/0001659617-19-000177-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000186/0001659617-19-000186-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961719000193/0001659617-19-000193-index.htm
2019-12-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000165961719000202/0001659617-19-000202-index.htm
2020-01-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000003/0001659617-20-000003-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000006/0001659617-20-000006-index.htm
2020-01-17S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000165961720000011/0001659617-20-000011-index.htm
2020-01-17S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000165961720000014/0001659617-20-000014-index.htm
2020-01-21RWRegistration Withdrawal Requesthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000016/0001659617-20-000016-index.htm
2020-02-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000023/0001659617-20-000023-index.htm
2020-02-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000026/0001659617-20-000026-index.htm
2020-02-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000034/0001659617-20-000034-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000038/0001659617-20-000038-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000043/0001659617-20-000043-index.htm
2020-03-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000047/0001659617-20-000047-index.htm
2020-03-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000050/0001659617-20-000050-index.htm
2020-03-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000055/0001659617-20-000055-index.htm
2020-03-1910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1659617/000165961720000066/0001659617-20-000066-index.htm
2020-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000068/0001659617-20-000068-index.htm
2020-03-23S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1659617/000165961720000076/0001659617-20-000076-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000079/0001659617-20-000079-index.htm
2020-03-27PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000083/0001659617-20-000083-index.htm
2020-04-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000087/0001659617-20-000087-index.htm
2020-04-07DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000090/0001659617-20-000090-index.htm
2020-04-07CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000092/0001659617-20-000092-index.htm
2020-04-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000094/0001659617-20-000094-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000097/0001659617-20-000097-index.htm
2020-04-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000102/0001659617-20-000102-index.htm
2020-04-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000106/0001659617-20-000106-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000110/0001659617-20-000110-index.htm
2020-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000113/0001659617-20-000113-index.htm
2020-05-08DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000122/0001659617-20-000122-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000124/0001659617-20-000124-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961720000128/0001659617-20-000128-index.htm
2020-05-15DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000132/0001659617-20-000132-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000134/0001659617-20-000134-index.htm
2020-05-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000138/0001659617-20-000138-index.htm
2020-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000140/0001659617-20-000140-index.htm
2020-06-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000144/0001659617-20-000144-index.htm
2020-06-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000147/0001659617-20-000147-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000151/0001659617-20-000151-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000152/0001659617-20-000152-index.htm
2020-06-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000153/0001659617-20-000153-index.htm
2020-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000158/0001659617-20-000158-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000161/0001659617-20-000161-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000165/0001659617-20-000165-index.htm
2020-07-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000171/0001659617-20-000171-index.htm
2020-07-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000172/0001659617-20-000172-index.htm
2020-07-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000173/0001659617-20-000173-index.htm
2020-07-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000178/0001659617-20-000178-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000181/0001659617-20-000181-index.htm
2020-07-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000183/0001659617-20-000183-index.htm
2020-08-048-K/ACurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000189/0001659617-20-000189-index.htm
2020-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1659617/000165961720000196/0001659617-20-000196-index.htm
2020-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000197/0001659617-20-000197-index.htm
2020-08-21S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000204/0001659617-20-000204-index.htm
2020-08-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000206/0001659617-20-000206-index.htm
2020-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1659617/000165961720000211/0001659617-20-000211-index.htm
2018-07-23EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1659617/999999999518001857/9999999995-18-001857-index.htm
2018-10-26EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1659617/999999999518002729/9999999995-18-002729-index.htm
2020-04-09EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1659617/999999999520000717/9999999995-20-000717-index.htm
2018-07-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1659617/999999999718006898/9999999997-18-006898-index.htm

Moleculin Biotech, Inc (MBRX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Moleculin Biotech, Inc (MBRX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1116%
Institutional Ownership: 2285%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-13WALTER V KLEMPCEO and PresidentBuy79,227.001,046,951.00https://www.sec.gov/Archives/edgar/data/1659617/000165961720000178/0001659617-20-000178-index.htm